DEEP RESEARCH · SAMSUNG BIOLOGICS
Samsung Biologics Deep Dive: CDMO Scale Advantage and Governance Reset
A review of 3Q25 performance, Songdo capacity, Biosecure Act exposure, and the Samsung Bioepis spin-off
0. Bottom line first
The key point, in my view, is that Samsung Biologics is moving beyond contract manufacturing into essential global biopharma infrastructure. Songdo capacity of 604,000 liters, Plant 4 ramp-up, Plant 5 expansion, and ADC modality expansion all point in the same direction.
Official fact: As of 3Q25, total capacity was presented as 604,000 liters. Cumulative 3Q25 consolidated revenue was KRW 3.2909 trillion and EBITDA was KRW 1.1115 trillion.
Interpretation: The Plant 4 ramp-up and large customer contracts suggest that the company has enough operating cash generation to absorb a heavy CAPEX cycle.
1. Industry position
In 2025, biopharma demand is being shaped by aging populations, chronic disease, blockbuster biologics in areas such as Alzheimer’s and obesity, and geopolitical supply-chain redesign. Pharma companies are increasingly relying on CDMO partners rather than expanding captive capacity at any cost.
Samsung Biologics was founded in Songdo, Incheon on April 22, 2011. Its core model combines antibody CMO with CDO services from cell-line development to clinical material production. Samsung Bioepis was also part of the group through 3Q25, but the planned spin-off changes that structure.
Commercial antibody production
Large bioreactors, quality systems, and long-term customer contracts are the core assets.
Early development support
Cell-line and process development create customer lock-in before commercial manufacturing.
Business to be separated
The spin-off separates biosimilar upside and patent risk from the CDMO entity.
2. Songdo capacity and CAPEX
Official fact: The company is pursuing a second Bio Campus project through 2032 with KRW 7.5 trillion of investment for Plants 5-8. Plant 5 was described as an 180,000-liter facility with KRW 2.01 trillion of investment.
| Item | Key figure | Meaning |
|---|---|---|
| Current capacity | 604,000 L | One of the world’s largest single-site production bases |
| Second Bio Campus | KRW 7.5tn through 2032 | Long-term growth capacity via Plants 5-8 |
| Plant 5 | 180,000 L, KRW 2.01tn | Expected automation and operating efficiency gains |
| 3Q25 cumulative EBITDA | KRW 1.1115tn | Evidence of funding capacity for expansion |
Interpretation: CDMO is a pre-investment industry. Expansion matters only when demand, utilization, and cash generation are visible together. I see Plant 4 and Plant 5 as part of the same capacity cycle.
3. Technology, quality, and modalities
To diversify beyond antibodies, the company began operating an ADC-dedicated production facility in 2024. With ADC licensing and M&A active across global pharma, the timing appears aligned with market formation. In CGT, the company is taking a more selective approach and considering options such as M&A or direct US/European entry.
New growth vector
A higher-value modality built on antibody manufacturing capabilities.
Selective entry
The company is weighing profitability and market readiness before committing.
Customer requirement
Net Zero 2050, RE100, 2024 zero-waste-to-landfill certification, ISO 37301 and ISO 27001 support non-financial risk management.
4. Risks and governance
Accounting litigation remains a monitoring item. The source discusses Securities and Futures Commission sanctions, a 2020 first-instance win on the first measure, and a Seoul Administrative Court cancellation ruling on August 14, 2024 for the second measure, followed by an appeal.
The Eylea biosimilar SB15 patent dispute is another example of biosimilar legal risk. The January 2025 US Federal Circuit and February 2025 Seoul Central District Court injunction decisions are relevant, but the planned spin-off should separate this risk from the remaining CDMO entity.
5. What I will keep watching
- Plant 5 orders and utilization ramp
- Whether Biosecure Act-driven supply-chain redesign turns into actual contracts
- Customer wins and revenue contribution from ADC facilities
- Pure-play CDMO valuation after the Samsung Bioepis spin-off
- Final accounting litigation outcomes and any restatement risk
Sources
- 구글드라이브 원문/자료 1: https://drive.google.com/open?id=1L78TL8oLL_iRr-qpX6tIr0GF4E1XrCfd6ukHQhxauQQ
- 구글드라이브 원문/자료 2: https://drive.google.com/open?id=1WBpEonLocqtCH9tx5HF2hWjkWGnizERg8i5Lp2exZ80
- 구글드라이브 원문/자료 3: https://drive.google.com/open?id=1MQOlYTpNJuA2UFoySBC9bM7W-gdp2INT
- 구글드라이브 원문/자료 4: https://drive.google.com/open?id=1x4V37txFH_LbJvYBbPYFpWtIx7QBtPTV